Bill Walsh Translational Cancer Research Laboratory

The Bill Walsh Translational Cancer Research Laboratory is the research arm of the Medical Oncology Department at Royal North Shore Hospital.

We focus on increasing our understanding of cancer biology and how cancer will behave. We are also working to identify better ways to diagnose cancer.

Through our research we are improving cancer treatment and offering better outcomes for those with the disease.


Lead

Department Heads

Associate Professor Nick Pavlakis Associate Professor Nick Pavlakis BSc, MBBS, MMed (Clin. Epi), PhD, FRACP

Appointment: Associate Professor, The University of Sydney Northern Clinical School, Faculty of Medicine and Health
Positions: Co-head, Bill Walsh Translational Cancer Research Laboratory; Chair, Scientific Advisory Committee, Australasian Lung Cancer Trials Group , Senior Staff Specialist, Dept. of Medical Oncology Royal North Shore

 Professor Stephen Clarke OAM, MBBS, PhD, MD, FRACP, FAChPM

Appointment: Professor, The University of Sydney Northern Clinical School, Faculty of Medicine and Health
Positions: Co-head, Bill Walsh Translational Cancer Research Laboratory; Senior Staff Specialist in Dept. Medical Oncology, Royal North Shore Hospital

Dr Helen Wheeler Dr Helen Wheeler MBBS, FRACP

Position: Co-head, Bill Walsh Translational Cancer Research Laboratory; Senior Staff Specialist, Head Dept. Medical Oncology, Royal North Shore Hospital

Research Director

Assoc Prof Viive Howell Associate Professor Viive Howell BSc (App), MSc, PhD

Appointment: Associate Professor, The University of Sydney Northern Clinical School, Faculty of Medicine and Health
Position: Laboratory Research Director, Bill Walsh Translational Cancer Research Laboratory; Co-Lead, Inflammation Flagship, Sydney Vital Translational Cancer Research Centre

Dr Emily Colvin Dr Emily Colvin BMedSc (Hons), PhD

Appointment: Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, The University of Sydney
Position: Proud Family Fellow and Cancer Institute NSW Early Career Fellow
Group Leader: Ovarian Cancer

Dr Connie Diakos Dr Connie Diakos BSc(Hons), PhD, MBBS, FRACP, MRACI CChem

Appointment: Conjoint Senior Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, The University of Sydney
Position: Research Fellow; Co-lead, Inflammation Flagship, Sydney Vital Translational Cancer Research Centre.
Group Leader: Colorectal Cancer, Neuroendocrine Cancer

Dr Amanda Hudson Dr Amanda Hudson BSc (Hons), PhD

Appointment: Research Fellow, Sydney Medical School (Northern), Faculty of Medicine and Health, The University of Sydney
Position: The Brain Cancer Group Fellow
Group Leader: Brain Cancer

Dr Kelly McKelvey Dr Kelly McKelvey BBiomedSci(Hons), PhD

Appointment: Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, University of Sydney
Position: Matt Callander ‘Beanie for Brain Cancer’ HMRI Fellow funded by the Mark Hughes Foundation
Group Leader: Radiation Therapy and Immunotherapy

Dr Sarah Hayes Dr Sarah Hayes BMedSc (Hons), PhD

Appointment: Associate Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, University of Sydney
Position: Tour de Cure / Fight for a Cure Early Career Research Fellow in lung cancer research
Group Leader: Lung Cancer and Proteomics

Dr Sumit Sahni Dr Sumit Sahni B.Pharma, PhD

Appointment: Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, University of Sydney
Position: Boncardo Pancreatic Cancer Research Fellow
Group Leader: Pancreatic Cancer

Dr Yaser Gholami Dr Yaser Gholami Medical Physics, PhD

Appointment: Associate Lecturer, School of Physics, University of Sydney
Position: Postdoctoral Scientist Nuclear Nanomedicine
Group Leader: Nanomedicine

Brain Cancer:

  1. Teaching an Old Drug New Tricks: Can we repurpose an old drug as a new brain cancer treatment?
  2. The immuno-coagulome: an untapped pathway for new therapeutics in glioma
  3. Investigating how glioblastoma tumours change over time to become resistant to treatment
  4. Unravelling the tumour micro-environment to combat brain cancer
  5. Laying the foundations for improved treatments for IDH-mutated glioma
  6. The interaction between coagulation, angiogenesis and inflammatory pathways in glioblastoma
  7. MHF Brain Cancer PACT: Mark Hughes Foundation Collaborative Brain Cancer Pre-clinical pipeline for Advancing Cancer Therapeutics
  8. Development of non-invasive monitoring for brain tumour recurrence and treatment resistance
  9. A new class of theranostics for malignant brain cancer
  10. Radiosensitisation of high-grade gliomas by modulating glucose metabolism
  11. New Horizons: Therapeutic applications for medicinal cannabis in the treatment of brain cancer

Colorectal Cancer:

  1. The role ofIinflammation in colorectal cancer
  2. Identifying prognostic protein markers in colorectal cancer tumour
  3. Exploring a new nanotechnology strategy for the neo-adjuvant treatment of colorectal cancer by photodynamic therapy and ionising radiation

Lung Cancer:

  1. Investigating patterns of drug resistance in ALK rearranged non-small cell lung cancer
  2. Exploring methods to improve efficacy of immunotherapy in non-small cell lung cancer
  3. Identification of biomarkers for non-small cell lung cancer
  4. Chemotherapy resistance in non-small cell lung cancer
  5. The exhaled breath condensate proteome: a promising source of biomarkers for lung cancer

Mesothelioma:

  1. Improved treatment for mesothelioma: Can cannabinoids address this unmet need?

Neuroendocrine Tumours:

  1. The role of dual PET scans in understanding neuroendocrine tumour behaviour
  2. Analysing PET scans for neuroendocrine tumours

Ovarian Cancer:

  1. Evaluation of lysyl oxidase inhibitors as a new treatment for ovarian cancer
  2. Investigating the role of long non-coding RNA (ribonucleic acid) in the ovarian cancer microenvironment
  3. Improving ovarian cancer treatment using nanoparticles

Pancreatic Cancer:

  1. Biomarker identification for pancreatic cancer diagnosis
  2. Biomarker identification for pancreatic cancer prognosis.
  3. Identification of new drug targets for pancreatic cancer treatment
  4. Understanding the role of tumour microenvironment in pancreatic cancer progression

Events, News and Seminars

International focus on our ovarian cancer research

International focus on our ovarian cancer research

In an exciting breakthrough, researchers from the Kolling Institute’s Bill Walsh Lab have identified..... Read more

Category: Research Excellence

Home grown ideas place physio in patients' hands

Home grown ideas place physio in patients' hands

New research is testing a new way to meet the rapidly growing demand for physiotherapy in our publi..... Read more

Category: New Treatment

Common medication may lower risk of “heartbreak”

Common medication may lower risk of “heartbreak”

RNSH cardiologist Professor Geoffrey Tofler has led a world-first study which found that common med..... Read more

Category: Research Excellence